Novo Nordisk A/S (NVO)

NYSE: NVO · Real-Time Price · USD
49.46
-0.58 (-1.16%)
At close: Oct 31, 2025, 4:00 PM EDT
49.74
+0.28 (0.57%)
After-hours: Oct 31, 2025, 6:25 PM EDT
-1.16%
Market Cap216.87B
Revenue (ttm)49.11B
Net Income (ttm)17.49B
Shares Out 4.44B
EPS (ttm)3.93
PE Ratio12.59
Forward PE13.23
Dividend$1.23 (2.49%)
Ex-Dividend DateAug 18, 2025
Volume19,991,318
Open48.78
Previous Close50.04
Day's Range48.49 - 49.47
52-Week Range45.05 - 113.02
Beta0.33
AnalystsBuy
Price Target80.40 (+62.56%)
Earnings DateNov 5, 2025

About NVO

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrin... [Read more]

Sector Healthcare
Founded 1923
Employees 77,349
Stock Exchange NYSE
Ticker Symbol NVO
Full Company Profile

Financial Performance

In 2024, Novo Nordisk's revenue was 290.40 billion, an increase of 25.03% compared to the previous year's 232.26 billion. Earnings were 100.99 billion, an increase of 20.68%.

Financial numbers in DKK Financial Statements

Analyst Summary

According to 10 analysts, the average rating for NVO stock is "Buy." The 12-month stock price target is $80.4, which is an increase of 62.56% from the latest price.

Price Target
$80.4
(62.56% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Pfizer has filed a lawsuit seeking to block Novo Nordisk from circumventing Pfizer's deal for weight-loss drug startup Metsera

The lawsuit says Novo Nordisk's offer for drug startup Metsera isn't reasonably likely to be completed.

Other symbols: MTSRPFE
1 hour ago - WSJ

Pfizer sues Metsera, Novo Nordisk over breach of merger deal

Pfizer on Friday filed a lawsuit against Metsera and Novo Nordisk , accusing them of breaking a merger agreement and interfering with the deal.

Other symbols: MTSRPFE
1 hour ago - Reuters

Novo Nordisk CEO says job cuts affecting 9,000 staff almost complete

Novo Nordisk has notified employees impacted by the drugmaker's job cuts in the vast majority of its locations although the pace varies according to local laws, its CEO Mike Doustdar wrote in a post o...

12 hours ago - Reuters

Two developments Thursday–Eli Lilly's strong quarterly performance and Novo Nordisk's unsolicited $9 billion bid for a startup–show why drugmakers can't get enough of weight loss

Lilly's quarterly results Thursday, combined with Novo Nordisk's unsolicited offer for a startup, confirm the $72 billion anti-obesity market is among pharma's hottest.

Other symbols: LLY
1 day ago - WSJ

Novo Nordisk changes tack with bold raid on Pfizer obesity deal

Novo Nordisk's late bid to hijack Pfizer's takeover of U.S. obesity biotech Metsera marks an aggressive shift from the Danish drugmaker as it seeks to regain ground in the weight-loss drug market unde...

Other symbols: PFEMTSR
1 day ago - Reuters

Metsera the US obesity biotech at centre of Novo, Pfizer bidding war

Metsera has become the obesity drug market's hottest ticket.

Other symbols: MTSRPFE
1 day ago - Reuters

Pfizer Blasts Novo Nordisk's $9 Billion Counteroffer For Metsera As 'Reckless'

On Thursday, Metsera Inc. (NASDAQ:MTSR) received an unsolicited acquisition proposal from Novo Nordisk A/S (NYSE:NVO).

Other symbols: MTSRPFE
1 day ago - Benzinga

Novo Nordisk says offer for Metsera adheres to restrictions under Pfizer deal

Novo Nordisk said on Thursday that it had adhered to all restrictions under the Pfizer merger agreement in its unsolicited offer for drugmaker Metsera , and that the value of its proposal far exceeded...

Other symbols: MTSRPFE
1 day ago - Reuters

Invesco EQV International Equity Fund Q3 2025 Performance Update

Invesco EQV International Equity Fund's Q3 2025 performance was driven by strong returns from TSM, Legrand, Trip.com, and Shenzhen Inovance. TSM outperformed on robust AI chip demand and favorable mar...

Other symbols: RELXSONYTCOMTSM
1 day ago - Seeking Alpha

Metsera Stock Soars. Novo Nordisk Looks to Outbid Pfizer for the Obesity-Drug Maker.

Denmark's Novo offers $56.50 a share in cash for Metsera, plus potentially a further $21.25 a share based on clinical and regulatory milestones.

Other symbols: MTSRPFE
1 day ago - Barrons

Pfizer Addresses Proposal for Metsera

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) is aware of the reckless and unprecedented proposal by Novo Nordisk A/S (NYSE: NVO) to acquire Metsera, Inc. (NASDAQ: MTSR). It is an attempt by a co...

Other symbols: MTSRPFE
1 day ago - Business Wire

Obesity drug rivalry heats up as Novo Nordisk tops Pfizer's bid for Metsera

In a move that highlights the escalating battle for dominance in the global weight-loss treatment market, Danish pharmaceutical giant Novo Nordisk A/S has made an improved takeover offer for US-based ...

Other symbols: PFE
1 day ago - Invezz

Novo Nordisk Moves to Outbid Pfizer With Up to $9 Billion Offer for Obesity Drug Developer Metsera

Novo Nordisk said the proposal is currently subject to review by Metsera's board of directors.

Other symbols: MTSRPFE
1 day ago - WSJ

Novo Nordisk makes unsolicited offer for Metsera

Denmark's Novo Nordisk said on Thursday it has made an unsolicited bid for U.S. drug maker Metsera.

Other symbols: MTSR
1 day ago - Reuters

Novo Nordisk submits proposal to acquire Metsera, Inc.

Bagsværd, Denmark, 30 October 2025 – Novo Nordisk confirms that it submitted an unsolicited proposal to acquire Metsera, Inc. (Metsera).

Other symbols: MTSR
1 day ago - GlobeNewsWire

Novo Nordisk said to make higher bid for Metsera to challenge Pfizer, Bloomberg News reports

Danish drugmaker Novo Nordisk has made a higher offer for Metsera seeking to trump an agreed deal with Pfizer so it can consolidate its position in weight-loss medications, Bloomberg News reported on ...

Other symbols: MTSRPFE
1 day ago - Reuters

Novo Nordisk: Decade-Low Valuation Meets A Billion-Patient Market

Initiating coverage on Novo Nordisk (NVO) with a Strong Buy 70% below its all-time high. NVO's competitive pressures and US political pricing risks are mid-term noise. Global obesity and diabetes mark...

7 days ago - Seeking Alpha

Focus: Novo Nordisk's new chairman has 'carte blanche' after board clear-out

A boardroom shake-up at Novo Nordisk has handed unprecedented power to its top shareholder, the Novo Nordisk Foundation, rattling investors despite calls for stronger leadership at the drugmaker behin...

7 days ago - Reuters

Eli Lilly Accelerates On Obesity Data While Novo Nordisk Retreats

Eli Lilly is a Strong Buy, driven by exceptional growth in obesity and diabetes drugs Mounjaro and Zepbound, plus pipeline innovation. LLY's diversified business mix, global reach, and proactive U.S. ...

Other symbols: LLY
8 days ago - Seeking Alpha

Novo Nordisk shares fall as top investor drives board overhaul

Shares in Novo Nordisk fell around 3% in early trading on Wednesday, extending their losses from a day earlier, after the Wegovy maker's top investor proposed a sweeping board overhaul.

9 days ago - Reuters

Novo's board bust-up to sharpen drugmaker's focus on US consumers

Boardroom drama at Wegovy-maker Novo Nordisk has laid bare the company's biggest challenge: how to better tap into America's mass market for weight-loss drugs.

9 days ago - Reuters

Healthy Returns: A key step forward for Novo Nordisk's GLP-1 pill

A closely watched pill from Novo Nordisk just scored an approval for slashing cardiovascular risks, while Mark Cuban gives Trump credit on drug prices.

10 days ago - CNBC

Who's on Novo Nordisk's board after major shakeup?

Novo Nordisk will replace chair Helge Lund and six independent directors next month in a major boardroom shakeup following a disagreement over strategy with its powerful controlling shareholder, Novo ...

10 days ago - Reuters

HSBC's Rajesh Kumar on Novo Nordisk: We want to see management team execute turnaround strategy

Rajesh Kumar, HSBC Sr. health care analyst, joins CNBC's 'Money Movers' to discuss his reaction to a board shakeup at Novo Nordisk.

10 days ago - CNBC Television

Novo Nordisk's Entire Board Is Stepping Down. Here's Why.

The board turmoil represents a breakdown in relations between the company and its controlling shareholder.

10 days ago - Barrons